{"url_path":"/sec/casif/10-k/2026/item-16a","section_key":"item-16a","section_title":"Item 16A AUDIT COMMITTEE FINANCIAL EXPERT**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1962738/0001104659-26-061632-index.html","accession_number":"0001104659-26-061632","cik":"0001962738","ticker":"CASIF","issuer_name":"CASI Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962738/0001104659-26-061632-index.html","primary_entity_key":"0001962738","primary_entity_name":"CASI Pharmaceuticals, Inc."},"word_count":42,"has_tables":true,"body_markdown":"**ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT**\n\nOur board of directors has determined that Thomas Folinsbee, the chairperson of our audit committee and an independent director (under Rule 10A-3 under the Exchange Act), is an audit committee financial expert.\n\n107\n\n[Table of Contents](#TOC)"}